Osteocalcin: A potential marker to identify and monitor girls with rapidly progressive central precocious puberty
Aim To evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non‐rapidly progressive central precocious puberty (RP‐CPP and NRP‐CPP), as well as its potential to assess growth rates following treatment with gonadotropin‐releasing hormone agonist (GnRHa). M...
Saved in:
Published in | Journal of paediatrics and child health Vol. 60; no. 10; pp. 593 - 600 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
John Wiley & Sons Australia, Ltd
01.10.2024
Blackwell Publishing Ltd |
Subjects | |
Online Access | Get full text |
ISSN | 1034-4810 1440-1754 1440-1754 |
DOI | 10.1111/jpc.16632 |
Cover
Abstract | Aim
To evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non‐rapidly progressive central precocious puberty (RP‐CPP and NRP‐CPP), as well as its potential to assess growth rates following treatment with gonadotropin‐releasing hormone agonist (GnRHa).
Methods
Serum levels of OC were measured using enzyme‐linked immunosorbent assays in girls diagnosed with either RP‐CPP or NRP‐CPP as well as in normal control subjects. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut‐off value for OC. Multivariate linear regression analysis was used to analyse the main influencing factors associated with OC.
Results
Serum OC levels were higher in the CPP girls when compared to normal controls (110.76 ± 43.69 vs 55.97 ± 20.96 ng/mL, P < 0.001). The level in the RP‐CPP group was higher than the NRP‐CPP group (153.28 ± 33.89 vs 88.33 ± 29.26 ng/mL, P < 0.001). The cut‐off value of OC levels for distinguishing between RP‐CPP and NRP‐CPP was 107.05 ng/mL, the sensitivity was 94.7% and the specificity was 77.8%, which was superior to using the basal luteinising hormone (B‐LH) levels, and the area under ROC curve (AUC) were 0.933 versus 0.695, respectively. Following 1–2 years of treatment with GnRHa for girls with CPP, both OC levels and the growth rates decreased to pre‐pubertal values. B‐LH levels, bone age and body weight were also significant factors, which affected OC levels.
Conclusions
Serum OC levels may be a useful marker for distinguishing RP‐CPP from NRP‐CPP. In addition, it was also found to be a useful predictor for growth rate during GnRHa treatment. |
---|---|
AbstractList | Aim
To evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non‐rapidly progressive central precocious puberty (RP‐CPP and NRP‐CPP), as well as its potential to assess growth rates following treatment with gonadotropin‐releasing hormone agonist (GnRHa).
Methods
Serum levels of OC were measured using enzyme‐linked immunosorbent assays in girls diagnosed with either RP‐CPP or NRP‐CPP as well as in normal control subjects. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut‐off value for OC. Multivariate linear regression analysis was used to analyse the main influencing factors associated with OC.
Results
Serum OC levels were higher in the CPP girls when compared to normal controls (110.76 ± 43.69 vs 55.97 ± 20.96 ng/mL, P < 0.001). The level in the RP‐CPP group was higher than the NRP‐CPP group (153.28 ± 33.89 vs 88.33 ± 29.26 ng/mL, P < 0.001). The cut‐off value of OC levels for distinguishing between RP‐CPP and NRP‐CPP was 107.05 ng/mL, the sensitivity was 94.7% and the specificity was 77.8%, which was superior to using the basal luteinising hormone (B‐LH) levels, and the area under ROC curve (AUC) were 0.933 versus 0.695, respectively. Following 1–2 years of treatment with GnRHa for girls with CPP, both OC levels and the growth rates decreased to pre‐pubertal values. B‐LH levels, bone age and body weight were also significant factors, which affected OC levels.
Conclusions
Serum OC levels may be a useful marker for distinguishing RP‐CPP from NRP‐CPP. In addition, it was also found to be a useful predictor for growth rate during GnRHa treatment. AimTo evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non‐rapidly progressive central precocious puberty (RP‐CPP and NRP‐CPP), as well as its potential to assess growth rates following treatment with gonadotropin‐releasing hormone agonist (GnRHa).MethodsSerum levels of OC were measured using enzyme‐linked immunosorbent assays in girls diagnosed with either RP‐CPP or NRP‐CPP as well as in normal control subjects. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut‐off value for OC. Multivariate linear regression analysis was used to analyse the main influencing factors associated with OC.ResultsSerum OC levels were higher in the CPP girls when compared to normal controls (110.76 ± 43.69 vs 55.97 ± 20.96 ng/mL, P < 0.001). The level in the RP‐CPP group was higher than the NRP‐CPP group (153.28 ± 33.89 vs 88.33 ± 29.26 ng/mL, P < 0.001). The cut‐off value of OC levels for distinguishing between RP‐CPP and NRP‐CPP was 107.05 ng/mL, the sensitivity was 94.7% and the specificity was 77.8%, which was superior to using the basal luteinising hormone (B‐LH) levels, and the area under ROC curve (AUC) were 0.933 versus 0.695, respectively. Following 1–2 years of treatment with GnRHa for girls with CPP, both OC levels and the growth rates decreased to pre‐pubertal values. B‐LH levels, bone age and body weight were also significant factors, which affected OC levels.ConclusionsSerum OC levels may be a useful marker for distinguishing RP‐CPP from NRP‐CPP. In addition, it was also found to be a useful predictor for growth rate during GnRHa treatment. To evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non-rapidly progressive central precocious puberty (RP-CPP and NRP-CPP), as well as its potential to assess growth rates following treatment with gonadotropin-releasing hormone agonist (GnRHa). Serum levels of OC were measured using enzyme-linked immunosorbent assays in girls diagnosed with either RP-CPP or NRP-CPP as well as in normal control subjects. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value for OC. Multivariate linear regression analysis was used to analyse the main influencing factors associated with OC. Serum OC levels were higher in the CPP girls when compared to normal controls (110.76 ± 43.69 vs 55.97 ± 20.96 ng/mL, P < 0.001). The level in the RP-CPP group was higher than the NRP-CPP group (153.28 ± 33.89 vs 88.33 ± 29.26 ng/mL, P < 0.001). The cut-off value of OC levels for distinguishing between RP-CPP and NRP-CPP was 107.05 ng/mL, the sensitivity was 94.7% and the specificity was 77.8%, which was superior to using the basal luteinising hormone (B-LH) levels, and the area under ROC curve (AUC) were 0.933 versus 0.695, respectively. Following 1-2 years of treatment with GnRHa for girls with CPP, both OC levels and the growth rates decreased to pre-pubertal values. B-LH levels, bone age and body weight were also significant factors, which affected OC levels. Serum OC levels may be a useful marker for distinguishing RP-CPP from NRP-CPP. In addition, it was also found to be a useful predictor for growth rate during GnRHa treatment. To evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non-rapidly progressive central precocious puberty (RP-CPP and NRP-CPP), as well as its potential to assess growth rates following treatment with gonadotropin-releasing hormone agonist (GnRHa).AIMTo evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non-rapidly progressive central precocious puberty (RP-CPP and NRP-CPP), as well as its potential to assess growth rates following treatment with gonadotropin-releasing hormone agonist (GnRHa).Serum levels of OC were measured using enzyme-linked immunosorbent assays in girls diagnosed with either RP-CPP or NRP-CPP as well as in normal control subjects. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value for OC. Multivariate linear regression analysis was used to analyse the main influencing factors associated with OC.METHODSSerum levels of OC were measured using enzyme-linked immunosorbent assays in girls diagnosed with either RP-CPP or NRP-CPP as well as in normal control subjects. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value for OC. Multivariate linear regression analysis was used to analyse the main influencing factors associated with OC.Serum OC levels were higher in the CPP girls when compared to normal controls (110.76 ± 43.69 vs 55.97 ± 20.96 ng/mL, P < 0.001). The level in the RP-CPP group was higher than the NRP-CPP group (153.28 ± 33.89 vs 88.33 ± 29.26 ng/mL, P < 0.001). The cut-off value of OC levels for distinguishing between RP-CPP and NRP-CPP was 107.05 ng/mL, the sensitivity was 94.7% and the specificity was 77.8%, which was superior to using the basal luteinising hormone (B-LH) levels, and the area under ROC curve (AUC) were 0.933 versus 0.695, respectively. Following 1-2 years of treatment with GnRHa for girls with CPP, both OC levels and the growth rates decreased to pre-pubertal values. B-LH levels, bone age and body weight were also significant factors, which affected OC levels.RESULTSSerum OC levels were higher in the CPP girls when compared to normal controls (110.76 ± 43.69 vs 55.97 ± 20.96 ng/mL, P < 0.001). The level in the RP-CPP group was higher than the NRP-CPP group (153.28 ± 33.89 vs 88.33 ± 29.26 ng/mL, P < 0.001). The cut-off value of OC levels for distinguishing between RP-CPP and NRP-CPP was 107.05 ng/mL, the sensitivity was 94.7% and the specificity was 77.8%, which was superior to using the basal luteinising hormone (B-LH) levels, and the area under ROC curve (AUC) were 0.933 versus 0.695, respectively. Following 1-2 years of treatment with GnRHa for girls with CPP, both OC levels and the growth rates decreased to pre-pubertal values. B-LH levels, bone age and body weight were also significant factors, which affected OC levels.Serum OC levels may be a useful marker for distinguishing RP-CPP from NRP-CPP. In addition, it was also found to be a useful predictor for growth rate during GnRHa treatment.CONCLUSIONSSerum OC levels may be a useful marker for distinguishing RP-CPP from NRP-CPP. In addition, it was also found to be a useful predictor for growth rate during GnRHa treatment. |
Author | Xie, Tao Lan, Dan Zeng, Dan Meng, Qi Chen, Yanfei Qin, Wei Sooranna, Suren R |
Author_xml | – sequence: 1 givenname: Wei orcidid: 0009-0000-5615-3151 surname: Qin fullname: Qin, Wei organization: The First Affiliated Hospital of Guangxi Medical University – sequence: 2 givenname: Yanfei surname: Chen fullname: Chen, Yanfei organization: The First Affiliated Hospital of Guangxi Medical University – sequence: 3 givenname: Suren R orcidid: 0000-0001-8562-9980 surname: Sooranna fullname: Sooranna, Suren R email: s.sooranna@imperial.ac.uk organization: Youjiang Medical University for Nationalities – sequence: 4 givenname: Dan surname: Zeng fullname: Zeng, Dan organization: The First Affiliated Hospital of Guangxi Medical University – sequence: 5 givenname: Tao surname: Xie fullname: Xie, Tao organization: The First Affiliated Hospital of Guangxi Medical University – sequence: 6 givenname: Qi surname: Meng fullname: Meng, Qi organization: The First Affiliated Hospital of Guangxi Medical University – sequence: 7 givenname: Dan orcidid: 0000-0001-5899-7040 surname: Lan fullname: Lan, Dan email: landan_ld@163.com organization: The First Affiliated Hospital of Guangxi Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39214861$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU1LxDAQhoMofh_8AxLwoodq0iRt1tuy-ImgBz2HNJlq1m5Tk1bpvzfrqgfBucwwPDO8vO8OWm99CwgdUHJKU53NO3NKi4Lla2ibck4yWgq-nmbCeMYlJVtoJ8Y5ISQXQm6iLTbJKZcF3UZv97EHb3RjXHuOp7jzPbS90w1e6PAKAfceO7tc1SPWrcUL37reB_zsQhPxh-tfcNCds82Iu-CfA8To3gGbdBLSly6A8cb5IeJuqCD04x7aqHUTYf-776Kny4vH2XV2d391M5veZYZRlmey0ERWUmhTaSt4XpeQS1ZpJrmuLLNQaFGLopDEWMqJyUVelpyLWksLknO2i45Xf5OstwFirxYuGmga3UKSoxiZTCQp6UQk9OgPOvdDaJM6xSgtkplcLqnDb2qoFmBVF1zyaFQ_ZibgZAWY4GMMUP8ilKhlUCoFpb6CSuzZiv1wDYz_g-r2Yba6-ASUGZTE |
Cites_doi | 10.1016/j.mce.2006.04.036 10.1186/s12885-019-5363-4 10.1507/endocrj.EJ17-0323 10.3390/ijms21207513 10.1084/jem.20171320 10.1530/EJE-14-0010 10.4274/jcrpe.galenos.2022.2022-12-11 10.1002/jcb.27767 10.1007/s00431-023-05174-y 10.1177/0009922814541807 10.6061/clinics/2019/e1205 10.1172/JCI65952 10.1515/IJAMH.2002.14.3.235 10.1186/s40510-017-0184-y 10.3389/fendo.2022.839895 10.1172/JCI153752 10.3390/ijms22041568 10.1007/s00198-015-3428-z 10.1007/s00198-013-2485-4 10.3389/fped.2021.610227 10.1016/j.jbior.2020.100752 10.6065/apem.2244062.031 10.3349/ymj.2019.60.12.1174 10.1056/NEJMcp0800459 10.1620/tjem.245.239 10.1038/s41574-019-0246-y 10.1515/jpem-2016-0243 10.1515/jpem-2019-0577 |
ContentType | Journal Article |
Copyright | 2024 Paediatrics and Child Health Division (The Royal Australasian College of Physicians). 2024 Paediatrics and Child Health Division (The Royal Australasian College of Physicians) |
Copyright_xml | – notice: 2024 Paediatrics and Child Health Division (The Royal Australasian College of Physicians). – notice: 2024 Paediatrics and Child Health Division (The Royal Australasian College of Physicians) |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ASE FPQ K6X K9. NAPCQ 7X8 |
DOI | 10.1111/jpc.16632 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed British Nursing Index British Nursing Index (BNI) (1985 to Present) British Nursing Index ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium British Nursing Index MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1440-1754 |
EndPage | 600 |
ExternalDocumentID | 39214861 10_1111_jpc_16632 JPC16632 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Guangxi Clinical Research Center of Pediatric Disease funderid: GUI KE AD22035219 – fundername: First Affiliated Hospital of Guangxi Medical University Starting Fund for Study Abroad Returnees funderid: 2010219 – fundername: First Affiliated Hospital of Guangxi Medical University Starting Fund for Study Abroad Returnees grantid: 2010219 – fundername: Guangxi Clinical Research Center of Pediatric Disease grantid: GUI KE AD22035219 |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO KTM LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOQ WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CITATION CGR CUY CVF ECM EIF NPM ASE FPQ K6X K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c3132-86a08b85acbad542f7e283ba384abd3de6a5f56680cd140c25277445fa8de8443 |
IEDL.DBID | DR2 |
ISSN | 1034-4810 1440-1754 |
IngestDate | Thu Sep 04 19:49:46 EDT 2025 Sat Jul 26 00:23:30 EDT 2025 Wed Aug 06 16:36:17 EDT 2025 Wed Oct 01 01:38:28 EDT 2025 Wed Jan 22 17:15:49 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | osteocalcin rapidly progressive growth rate girls central precocious puberty |
Language | English |
License | 2024 Paediatrics and Child Health Division (The Royal Australasian College of Physicians). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3132-86a08b85acbad542f7e283ba384abd3de6a5f56680cd140c25277445fa8de8443 |
Notes | Conflict of interest: None declared. Author contributions: WQ and YC analysed the results and drafted the manuscript. WQ, YC and DZ completed the experimental part of this study and summarised all the information. DL and SRS participated in the study design and modified the manuscript. DZ, TX and QM performed the specimen collection. All the authors approved the final manuscript. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0009-0000-5615-3151 0000-0001-5899-7040 0000-0001-8562-9980 |
PMID | 39214861 |
PQID | 3116754485 |
PQPubID | 49064 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_3099807195 proquest_journals_3116754485 pubmed_primary_39214861 crossref_primary_10_1111_jpc_16632 wiley_primary_10_1111_jpc_16632_JPC16632 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2024 2024-10-00 20241001 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: October 2024 |
PublicationDecade | 2020 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia – name: Oxford |
PublicationTitle | Journal of paediatrics and child health |
PublicationTitleAlternate | J Paediatr Child Health |
PublicationYear | 2024 |
Publisher | John Wiley & Sons Australia, Ltd Blackwell Publishing Ltd |
Publisher_xml | – name: John Wiley & Sons Australia, Ltd – name: Blackwell Publishing Ltd |
References | 2021; 9 2017; 64 2002; 14 2022; 132 2023; 182 2021; 22 2019; 74 2018; 245 2019; 15 2015; 54 2013; 123 2014; 25 2019; 19 2020; 78 2020; 33 2014; 170 2017; 214 2019; 120 2006; 254‐255 2017; 30 2019; 60 2023; 28 2022; 60 2022; 13 2022; 14 2008; 358 2017; 18 2020; 21 2016; 27 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_30_1 e_1_2_10_29_1 Xu XQ (e_1_2_10_25_1) 2022; 60 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_26_1 |
References_xml | – volume: 27 start-page: 1619 year: 2016 end-page: 1629 article-title: Associations between adiposity, hormones, and gains in height, whole‐body height‐adjusted bone size, and size‐adjusted bone mineral content in 8‐ to 11‐year‐old children publication-title: Osteoporos. Int. – volume: 14 start-page: 235 year: 2002 end-page: 244 article-title: Osteocalcin. A biochemical marker of bone turnover during puberty publication-title: Int. J. Adolesc. Med. Health – volume: 21 year: 2020 article-title: Functions of osteocalcin in bone, pancreas, testis, and muscle publication-title: Int. J. Mol. Sci. – volume: 245 start-page: 239 year: 2018 end-page: 243 article-title: Serum osteocalcin levels in girls with central precocious puberty: Relation to the onset of puberty publication-title: Tohoku J. Exp. Med. – volume: 15 start-page: 651 year: 2019 end-page: 665 article-title: The role of osteoblasts in energy homeostasis publication-title: Nat. Rev. Endocrinol. – volume: 214 start-page: 2859 year: 2017 end-page: 2873 article-title: Gpr158 mediates osteocalcin's regulation of cognition publication-title: J. Exp. Med. – volume: 60 start-page: 311 year: 2022 end-page: 316 article-title: Relationship between body mass index and sexual development in Chinese children publication-title: Zhonghua Er Ke Za Zhi – volume: 74 year: 2019 article-title: Clinical and laboratory parameters of gonadotropin‐releasing hormone analog treatment effectiveness in children with precocious puberty publication-title: Clinics (Sao Paulo) – volume: 22 year: 2021 article-title: Critical role of estrogens on bone homeostasis in both male and female: From physiology to medical implications publication-title: Int. J. Mol. Sci. – volume: 132 year: 2022 article-title: Embryonic osteocalcin signaling determines lifelong adrenal steroidogenesis and homeostasis in the mouse publication-title: J. Clin. Invest. – volume: 60 start-page: 1174 year: 2019 end-page: 1180 article-title: Serum procollagen type I N‐terminal propeptide and osteocalcin levels in Korean children and adolescents publication-title: Yonsei Med. J. – volume: 120 start-page: 4924 year: 2019 end-page: 4934 article-title: Roles for osteocalcin in proliferation and differentiation of spermatogonial cells cocultured with somatic cells publication-title: J. Cell. Biochem. – volume: 19 year: 2019 article-title: Autocrine production of reproductive axis neuropeptides affects proliferation of canine osteosarcoma in vitro publication-title: BMC Cancer – volume: 54 start-page: 414 year: 2015 end-page: 424 article-title: A pediatrician's guide to central precocious puberty publication-title: Clin. Pediatr. – volume: 182 start-page: 5007 year: 2023 end-page: 5013 article-title: Analysis of serum insulin‐like growth factor‐1, fibroblast growth factor 23, and Klotho levels in girls with rapidly progressive central precocious puberty publication-title: Eur. J. Pediatr. – volume: 9 year: 2021 article-title: Serum and urinary osteocalcin in healthy 7‐ to 19‐year‐old Finnish children and adolescents publication-title: Front. Pediatr. – volume: 14 start-page: 302 year: 2022 end-page: 307 article-title: Has the frequency of precocious puberty and rapidly progressive early puberty increased in girls during the COVID‐19 pandemic? publication-title: J. Clin. Res. Pediatr. Endocrinol. – volume: 78 year: 2020 article-title: The roles ofosteocalcin in lipid metabolism in adipose tissue and liver publication-title: Adv Biol Regul – volume: 170 start-page: 749 year: 2014 end-page: 758 article-title: The diagnostic value of first‐voided urinary LH compared with GNRH‐stimulated gonadotropins in differentiating slowly progressive from rapidly progressive precocious puberty in girls publication-title: Eur. J. Endocrinol. – volume: 28 start-page: 178 year: 2023 end-page: 183 article-title: Slower progression of central puberty in overweight girls presenting with precocious breast development publication-title: Ann. Pediatr. Endocrinol. Metab. – volume: 254‐255 start-page: 32 year: 2006 end-page: 38 article-title: Development of GABA and glutamate signaling at the GnRH neuron in relation to puberty publication-title: Mol. Cell. Endocrinol. – volume: 33 start-page: 785 year: 2020 end-page: 791 article-title: Rapid progressivecentral precocious puberty: Diagnostic and predictive value of basal sex hormone levels and pelvic ultrasound publication-title: J. Pediatr. Endocrinol. Metab. – volume: 25 start-page: 729 year: 2014 end-page: 736 article-title: Reference values of osteocalcin and procollagen type I N‐propeptide plasma levels in a healthy central European population aged 0‐18 years publication-title: Osteoporos. Int. – volume: 18 year: 2017 article-title: Osteocalcin and serum insulin‐like growth factor‐1 as biochemical skeletal maturity indicators publication-title: Prog. Orthod. – volume: 30 start-page: 141 year: 2017 end-page: 147 article-title: Plasma concentrations of osteocalcin are associated with the timing of pubertal progress in boys publication-title: J. Pediatr. Endocrinol. Metab. – volume: 358 start-page: 2366 year: 2008 end-page: 2377 article-title: Clinical practice. Precocious puberty publication-title: N. Engl. J. Med. – volume: 64 start-page: 1043 year: 2017 end-page: 1053 article-title: Interaction between bone and glucose metabolism publication-title: Endocr. J. – volume: 123 start-page: 2421 year: 2013 end-page: 2433 article-title: Osteocalcin regulates murine and human fertility through a pancreas‐bone‐testis axis publication-title: J. Clin. Invest. – volume: 13 year: 2022 article-title: Difference of precocious puberty between before and during the COVID‐19 pandemic: A cross‐sectional study among Shanghai school‐aged girls publication-title: Front. Endocrinol. – ident: e_1_2_10_13_1 doi: 10.1016/j.mce.2006.04.036 – ident: e_1_2_10_23_1 doi: 10.1186/s12885-019-5363-4 – ident: e_1_2_10_8_1 doi: 10.1507/endocrj.EJ17-0323 – ident: e_1_2_10_6_1 doi: 10.3390/ijms21207513 – ident: e_1_2_10_10_1 doi: 10.1084/jem.20171320 – ident: e_1_2_10_20_1 doi: 10.1530/EJE-14-0010 – ident: e_1_2_10_2_1 doi: 10.4274/jcrpe.galenos.2022.2022-12-11 – ident: e_1_2_10_9_1 doi: 10.1002/jcb.27767 – ident: e_1_2_10_5_1 doi: 10.1007/s00431-023-05174-y – ident: e_1_2_10_18_1 doi: 10.1177/0009922814541807 – ident: e_1_2_10_21_1 doi: 10.6061/clinics/2019/e1205 – ident: e_1_2_10_12_1 doi: 10.1172/JCI65952 – ident: e_1_2_10_28_1 doi: 10.1515/IJAMH.2002.14.3.235 – ident: e_1_2_10_29_1 doi: 10.1186/s40510-017-0184-y – volume: 60 start-page: 311 year: 2022 ident: e_1_2_10_25_1 article-title: Relationship between body mass index and sexual development in Chinese children publication-title: Zhonghua Er Ke Za Zhi – ident: e_1_2_10_3_1 doi: 10.3389/fendo.2022.839895 – ident: e_1_2_10_11_1 doi: 10.1172/JCI153752 – ident: e_1_2_10_24_1 doi: 10.3390/ijms22041568 – ident: e_1_2_10_30_1 doi: 10.1007/s00198-015-3428-z – ident: e_1_2_10_14_1 doi: 10.1007/s00198-013-2485-4 – ident: e_1_2_10_15_1 doi: 10.3389/fped.2021.610227 – ident: e_1_2_10_7_1 doi: 10.1016/j.jbior.2020.100752 – ident: e_1_2_10_26_1 doi: 10.6065/apem.2244062.031 – ident: e_1_2_10_22_1 doi: 10.3349/ymj.2019.60.12.1174 – ident: e_1_2_10_19_1 doi: 10.1056/NEJMcp0800459 – ident: e_1_2_10_16_1 doi: 10.1620/tjem.245.239 – ident: e_1_2_10_27_1 doi: 10.1038/s41574-019-0246-y – ident: e_1_2_10_17_1 doi: 10.1515/jpem-2016-0243 – ident: e_1_2_10_4_1 doi: 10.1515/jpem-2019-0577 |
SSID | ssj0002558 |
Score | 2.3968647 |
Snippet | Aim
To evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non‐rapidly progressive central precocious puberty... To evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non-rapidly progressive central precocious puberty (RP-CPP... AimTo evaluate the suitability of serum osteocalcin (OC) as a marker to distinguish between rapidly and non‐rapidly progressive central precocious puberty... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 593 |
SubjectTerms | Biomarkers Biomarkers - blood Case-Control Studies central precocious puberty Child Endocrine disorders Enzyme-Linked Immunosorbent Assay Female Girls Gonadotropin-Releasing Hormone growth rate Humans Medical diagnosis osteocalcin Osteocalcin - blood Pediatrics Peptides Puberty Puberty, Precocious - blood Puberty, Precocious - diagnosis Puberty, Precocious - drug therapy rapidly progressive ROC Curve |
Title | Osteocalcin: A potential marker to identify and monitor girls with rapidly progressive central precocious puberty |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjpc.16632 https://www.ncbi.nlm.nih.gov/pubmed/39214861 https://www.proquest.com/docview/3116754485 https://www.proquest.com/docview/3099807195 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1034-4810 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1440-1754 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002558 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS-UwEB7Eh8UXdb0edSWKD7700KZJT7r7JLIighdEwQeh5FY5qD21pwrur99J2h5vCOJbLwlpMpnkm8w3U4AdHpo8VZoFKc1VgJoYBUo5lgUuhFxEOkwHLjj5-CQ5vGRHV_xqCv50sTBNfojJgZvTDL9eOwWXavxayUvdj3C_dOtvFHPvoj1_SR2FULkNg2MBE1HYZhXyLJ6u5tu96APAfItX_YZzMAfX3ac2PJPb_mOt-vrfuyyO3-zLPMy2QJTsNTPnJ0zZYgF-HLeu9kV4OEX5u40Ob3-TPVKOakcswir3jtFTkXpEhj7KN38msjDk3q8OFbkZVndj4s53SSXLobl7Jp4E5vi2T5a0bFB8hoavdgxcguPgMvwuweXB34v9w6D9P0OgXcLHQCQyFEpwqZU0nNF8YBGsKBkLJpWJjU0kzxEuilAbtOM05RTBJuO5FMYKxuJlmC5GhV0FwoShxlCltGUstKlIBkkeUSqt4EqHtAfbnaSysknDkU3Ml1JnfvB6sNHJMGs1cZzFztHE0QjlPdiavEYdco4RWVjsZhYjTBaItVIss9LIftIK4ke0GJOoB7tegp83nx2d7fuLta8XXYcZiiipYQduwHRdPdpfiHJqtemn83_-OPjV |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRQIu5U2XFjCIA5esEsfOOohLVaiW0i0ItVIvKPIraNU2m6YpUvvrmXGShYKQELc8bDn2eDzf2N9MAF7J2JW5sSLKeWki1MQkMoZYFrgQSpXYOJ9QcPJsP5seit0jebQCb4dYmC4_xHLDjTQjrNek4LQh_auW13acoMHEBfgGnc-RWr778jN5FILlPhBOREIlcZ9XKPB4hqrXrdEfEPM6Yg0mZ-cOfB0-tmOaHI8vWjO2V7_lcfzf3tyFtR6Lsq1u8tyDFV_dh5uz_rT9AZx9wilAtg5v37AtVi9a4hZhlVMi9TSsXbB5CPQtL5muHDsNC0TDvs2bk3NGW7ys0fXcnVyywAMjyu13z3pCKD5D39cSCZfhQFCS34dwuPP-YHsa9b9oiCzlfIxUpmNllNTWaCcFLyce8YrRqRLauNT5TMsSEaOKrUNXznLJEW8KWWrlvBIifQSr1aLy68CEctw5boz1QsQ-V9kkKxPOtVfS2JiP4OUgqqLuMnEUSw-mtkUYvBFsDkIsemU8L1I6a5Loh8oRvFi-RjWisxFdeexmkSJSVgi3cizzuBP-shWEkOg0ZskIXgcR_r35Yvfzdrh48u9Fn8Ot6cFsr9j7sP9xA25zBE0dWXATVtvmwj9F0NOaZ2Fu_wCDmvzx |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hKiEubaFQtt0WF3HgklXi2FmnPSHoitLyEAKJA1LkV6pVIZuGUGn59YydZFtASKi3PGw5fszMN_Y3E4BNHpo8VZoFKc1VgJIYBUo5lgUqQi4iHaZDF5x8cJjsnbH9c34-B1-6WJgmP8Rsw81JhtfXTsBLk_8r5KUeRGgvUf--YAl6Vw4RnfzNHYVYuY2DYwETUdimFfI0nq7qfWP0CGHeB6ze4oxewUX3rQ3R5NfgplYDffsgjeN_duY1vGyRKNluls4SzNliGRYO2rP2N_D7CBeAs3R4-5lsk3JSO2YRVrlylJ6K1BMy9mG--ZTIwpArrx4q8nNcXV4Tt8FLKlmOzeWUeBaYI9z-saSlg-Iz9Hy1o-ASHAeX4ncFzkZfT3f2gvYHDYF2GR8DkchQKMGlVtJwRvOhRbSiZCyYVCY2NpE8R7woQm3QkdOUU0SbjOdSGCsYi1dhvpgUdg0IE4YaQ5XSlrHQpiIZJnlEqbSCKx3SHmx0M5WVTR6ObOa_lDrzg9eDfjeHWSuK11nsTpo4eqG8B59mr1GI3MmILCx2M4sRJwsEWymWedvM_awVBJDoMiZRD7b8DD7dfLZ_vOMv3j2_6DosHO-Osh_fDr-_h0WKiKlhCvZhvq5u7AdEPLX66Ff2HZfM-6A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Osteocalcin%3A+A+potential+marker+to+identify+and+monitor+girls+with+rapidly+progressive+central+precocious+puberty&rft.jtitle=Journal+of+paediatrics+and+child+health&rft.au=Qin%2C+Wei&rft.au=Chen%2C+Yanfei&rft.au=Sooranna%2C+Suren+R&rft.au=Zeng%2C+Dan&rft.date=2024-10-01&rft.eissn=1440-1754&rft.volume=60&rft.issue=10&rft.spage=593&rft_id=info:doi/10.1111%2Fjpc.16632&rft_id=info%3Apmid%2F39214861&rft.externalDocID=39214861 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1034-4810&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1034-4810&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1034-4810&client=summon |